Arthroject solution 100mg/ml 2ml ampoules, 10pcs

Composition

Per 1 ml:

Active ingredient:

chondroitin sodium sulfate – 100 mg;

excipients: benzyl alcohol 12.0 mg,0.1 M sodium hydroxide solution or 0.1 M hydrochloric acid solution – up to pH 6.0-7.5, water for injection up to 1.0 ml

Pharmacological action

Pharmacotherapy group: tissue repair stimulator

ATX code: M01AX25.

Pharmacological properties

Pharmacodynamics

It has chondrostimulating, regenerating, anti-inflammatory and analgesic effects. Chondroitin sulfate is involved in the construction of the main substance of cartilage and bone tissue. It has chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, subchondral bone; inhibits enzymes that cause degeneration (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes. It reduces the release of inflammatory mediators and pain factors into the synovial fluid, suppresses the secretion of leukotrienes and prostaglandins. Slows down bone resorption and reduces calcium loss, accelerates the processes of bone recovery.

Chondroitin sulfate slows down the progression of osteoarthritis and osteochondrosis. Promotes the restoration of the articular bag and cartilage surfaces of joints, prevents the collapse of connective tissue, normalizes the production of joint fluid.

When using the drug, pain decreases and mobility of the affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy. In the treatment of degenerative joint changes accompanied by secondary synovitis, the effect is observed after 2-3 weeks from the start of the course.

Having a structural similarity to heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculation.

Pharmacokinetics

30 minutes after intramuscular use is detected in the blood in significant concentrations; after 15 minutes-in synovial fluid. The maximum concentration in blood plasma (cmax) is reached after 1 h, then the concentration of the drug gradually decreases over 2 days.

It accumulates mainly in the cartilage tissue (the maximum concentration in the articular cartilage is reached after 48 hours); the synovial membrane is not an obstacle to the penetration of the drug into the joint cavity. It is excreted by the kidneys.

Indications

Degenerative-dystrophic diseases of the joints and spine:

– osteoarthritis of the peripheral joints—

– intervertebral osteochondrosis and osteoarthritis.

To accelerate the formation of bone callus in fractures.

Use during pregnancy and lactation

It is not recommended to use the drug during pregnancy.

If it is necessary to use the drug during breastfeeding, breast-feeding should be discontinued due to lack of data.

Contraindications

-Increased individual sensitivity to chondroitin sulfate and any of the components of the drug;

– bleeding, a tendency to bleeding;

– thrombophlebitis;

– children under 18 years of age (efficacy and safety have not been established).

Side effects

Allergic reactions (pruritus, rash, erythema, urticaria, dermatitis, edema); bleeding at the injection site.

Interaction

It is possible to increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics.

How to take, course of use and dosage

The drug is administered intramuscularly at 100 mg (1 ml) every other day. If well tolerated, the dose is increased to 200 mg (2 ml), starting with the fourth injection.

The course of treatment is 25-35 injections.

If necessary, a second course of treatment is possible after 6 months.

Overdose

Currently, no cases of overdose with chondroitin sulfate have been reported.

Description

Clear, colorless or slightly yellowish solution.

Special instructions

When the drug is co-administered with indirect anticoagulants, antiplatelet agents, and fibrinolytics, more frequent monitoring of blood clotting parameters is required.

In case of allergic reactions or hemorrhages, treatment should be discontinued.

To achieve a stable clinical effect, at least 25 injections of the drug are required, but the effect persists for a long time for several months after the end of the course of treatment. Repeated courses of treatment are indicated to prevent exacerbations.

Influence on the ability to drive vehicles and mechanisms

It does not affect the ability to drive vehicles and mechanisms.

Storage conditions

Store in a dark place at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf

life is 2.5 years. Do not use after the expiration date indicated on the package.

Active ingredient

Chondroitin sulfate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection